ZA972232B - A method of prophylaxis and/or treatment. - Google Patents

A method of prophylaxis and/or treatment.

Info

Publication number
ZA972232B
ZA972232B ZA9702232A ZA972232A ZA972232B ZA 972232 B ZA972232 B ZA 972232B ZA 9702232 A ZA9702232 A ZA 9702232A ZA 972232 A ZA972232 A ZA 972232A ZA 972232 B ZA972232 B ZA 972232B
Authority
ZA
South Africa
Prior art keywords
mammal
useful
prophylaxis
treatment
coxiella
Prior art date
Application number
ZA9702232A
Other languages
English (en)
Inventor
William Butler Cowden
Kevin John Lafferty
Lawrence Scott Gazda
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Australian filed Critical Univ Australian
Publication of ZA972232B publication Critical patent/ZA972232B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA9702232A 1996-03-14 1997-03-14 A method of prophylaxis and/or treatment. ZA972232B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN8703A AUPN870396A0 (en) 1996-03-14 1996-03-14 Treatment of auto-immune insulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
ZA972232B true ZA972232B (en) 1997-11-18

Family

ID=3793016

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9702232A ZA972232B (en) 1996-03-14 1997-03-14 A method of prophylaxis and/or treatment.

Country Status (9)

Country Link
US (1) US6790450B1 (fr)
EP (1) EP0886528B1 (fr)
JP (1) JP2000506172A (fr)
AT (1) ATE279945T1 (fr)
AU (1) AUPN870396A0 (fr)
DE (1) DE69731284D1 (fr)
NZ (2) NZ503143A (fr)
WO (1) WO1997033614A1 (fr)
ZA (1) ZA972232B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057534A2 (fr) * 2000-02-04 2001-08-09 Bioseek Compositions et methodes de reduction de l'auto-immunite
CN1218750C (zh) 2003-06-06 2005-09-14 长春生物制品研究所 皮内注射用重组乙型肝炎卡介苗联合疫苗及制备方法
GB201517019D0 (en) * 2015-09-25 2015-11-11 Sec Dep For Health The Coxiella burnetii antigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331355C (fr) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentialisation
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
AU5960096A (en) * 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t ce lls

Also Published As

Publication number Publication date
ATE279945T1 (de) 2004-11-15
NZ331536A (en) 2000-07-28
JP2000506172A (ja) 2000-05-23
AUPN870396A0 (en) 1996-04-04
EP0886528A4 (fr) 1999-06-02
US6790450B1 (en) 2004-09-14
NZ503143A (en) 2001-06-29
DE69731284D1 (de) 2004-11-25
EP0886528A1 (fr) 1998-12-30
EP0886528B1 (fr) 2004-10-20
WO1997033614A1 (fr) 1997-09-18

Similar Documents

Publication Publication Date Title
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
CA2113476A1 (fr) Remplacement de la valvule sigmoide endovasculaire
CA2072624A1 (fr) Traitement de l'obesite a l'aide d'un agoniste alpha-2 adrenergique et d'un peptide liberant l'hormone de croissance
EP2269616A3 (fr) Surnageant issu de cellules souches mesenchymateuses pour la prévention et le traitement de réponses immunitaires lors de greffes
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
GB9414305D0 (en) Alginate fibre, process for the preparation thereof and use
BG104091A (en) Cd154 blockade therapty in tissue transplantation of pancreatic isles
HU901516D0 (en) The use of s-adenosile-methionine in the treatment of pancreatitis, and in preventing the natural rejection of transplanted pancreas
BG104135A (en) Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion
KR0166663B1 (en) Use of il-10 to prevent insulin-dependent diabetes mellitus
ZA972232B (en) A method of prophylaxis and/or treatment.
WO2003102162A3 (fr) Nouvelles cellules dendritiques tolerogeniques et utilisations therapeutiques de celles-ci
AU2002952492A0 (en) Chaperonin 10 immunosuppression
GB9414304D0 (en) Fibres, manufacture and use
IL111196A0 (en) Peptides and pharmaceutical compositions comprising them
ES2108122T3 (es) Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
HU9300243D0 (en) 1-(b-d-arabino-furanosyl)-5-propinyl-uracyl compounds
Timm et al. Short‐term immunosuppression after rat parathyroid allotransplantation
ATE197764T1 (de) Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
PL327472A1 (en) Nitrogen oxide (no) synthase inhibitor for use in treatment or polphylaxy of type ii diabetes
EP0308717A3 (en) Method of treating viral encephalitis
Andrews Survival of ornamental fish in natural and semi natural waters at Amatikulu Hatchery
NZ503559A (en) Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor
ATE253378T1 (de) Xenogene transplantation